Article Details

Cortexyme (NASDAQ:CRTX) Rating Increased to Hold at Zacks Investment Research

Retrieved on: 2021-05-15 22:41:15

Tags for this article:

Click the tags to see associated articles and topics

Cortexyme (NASDAQ:CRTX) Rating Increased to Hold at Zacks Investment Research. View article details on hiswai:

Excerpt

BlackRock Inc. now owns 1,362,139 shares of the biopharmaceutical company's stock worth $37,841,000 after acquiring an additional 400,761 shares ...

Article found on: www.marketbeat.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up